---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-324786"
form_type: "8-K/A"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2026-07-30T10:02:24+00:00"
generated_at: "2026-07-30T10:10:46.846390+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics files Orphai acquisition financials; pipeline details disclosed

## Summary
- Audited Orphai financials for FY2024-2025 and unaudited Q1 2026 now filed; pro forma combined financials included.
- Lead asset LAM-001 (inhaled rapamycin) targets PH-ILD, BOS, and SAPH; Phase 2b PH-ILD data expected Q1 2028.
- Phase 2 BOS trial fully enrolled, preliminary data expected Q1 2027; SAPH Phase 2 to start late 2026.
- Acquisition funded by $115M upfront private placement; potential additional $83M from warrant exercises.
- Orphai's former COO Keith Fandrick joins as Head of Technical Operations; Brigette Roberts remains Chief Corporate Affairs Officer.

## SEC filing metadata
- accession: 0001193125-26-324786
- form_type: 8-K/A
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2026-07-30T10:02:24+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312526324786/0001193125-26-324786-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312526324786/d163930d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-324786
- JSON: https://secwatch.observer/filing/0001193125-26-324786.json
- Plain text: https://secwatch.observer/filing/0001193125-26-324786.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.